是时候重新考虑治疗大疱性类天疱疮的利妥昔单抗剂量方案了吗？

IF 3 Q3 IMMUNOLOGY

Antibodies Pub Date : 2024-01-05 DOI:10.3390/antib13010004

Christian Ciolfi, Jacopo Tartaglia, Mauro Alaibac

{"title":"是时候重新考虑治疗大疱性类天疱疮的利妥昔单抗剂量方案了吗？","authors":"Christian Ciolfi, Jacopo Tartaglia, Mauro Alaibac","doi":"10.3390/antib13010004","DOIUrl":null,"url":null,"abstract":"Rituximab is currently approved for patients affected by moderate-to-severe pemphigus vulgaris, a severe autoimmune blistering skin disease that can be life-threatening. The standard rituximab dosing regimens, originally established for B-cell non-Hodgkin’s lymphomas, have been recognized to exceed the effective dose required for inducing B-cell depletion, considering that the B-cell burden in pemphigus vulgaris is considerably lower than in lymphoproliferative disorders. We herein report our experience with very ultra-low-dose rituximab in two patients affected by pemphigus vulgaris.","PeriodicalId":8188,"journal":{"name":"Antibodies","volume":"38 39","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2024-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Is It Time to Reconsider Rituximab Dosing Regimens for Pemphigus Vulgaris?\",\"authors\":\"Christian Ciolfi, Jacopo Tartaglia, Mauro Alaibac\",\"doi\":\"10.3390/antib13010004\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Rituximab is currently approved for patients affected by moderate-to-severe pemphigus vulgaris, a severe autoimmune blistering skin disease that can be life-threatening. The standard rituximab dosing regimens, originally established for B-cell non-Hodgkin’s lymphomas, have been recognized to exceed the effective dose required for inducing B-cell depletion, considering that the B-cell burden in pemphigus vulgaris is considerably lower than in lymphoproliferative disorders. We herein report our experience with very ultra-low-dose rituximab in two patients affected by pemphigus vulgaris.\",\"PeriodicalId\":8188,\"journal\":{\"name\":\"Antibodies\",\"volume\":\"38 39\",\"pages\":\"\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2024-01-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Antibodies\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3390/antib13010004\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Antibodies","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/antib13010004","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

利妥昔单抗目前被批准用于治疗中重度寻常性天疱疮患者，这是一种严重的自身免疫性大疱性皮肤病，可危及生命。利妥昔单抗的标准剂量方案最初是为 B 细胞非霍奇金淋巴瘤制定的，但考虑到寻常型天疱疮的 B 细胞负担远低于淋巴组织增生性疾病，该方案被认为超出了诱导 B 细胞耗竭所需的有效剂量。我们在此报告两名寻常型丘疹性荨麻疹患者使用超低剂量利妥昔单抗的经验。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Is It Time to Reconsider Rituximab Dosing Regimens for Pemphigus Vulgaris?

Rituximab is currently approved for patients affected by moderate-to-severe pemphigus vulgaris, a severe autoimmune blistering skin disease that can be life-threatening. The standard rituximab dosing regimens, originally established for B-cell non-Hodgkin’s lymphomas, have been recognized to exceed the effective dose required for inducing B-cell depletion, considering that the B-cell burden in pemphigus vulgaris is considerably lower than in lymphoproliferative disorders. We herein report our experience with very ultra-low-dose rituximab in two patients affected by pemphigus vulgaris.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Antibodies IMMUNOLOGY-

CiteScore

7.10

自引率

6.40%

发文量

审稿时长

11 weeks

期刊介绍： Antibodies (ISSN 2073-4468), an international, peer-reviewed open access journal which provides an advanced forum for studies related to antibodies and antigens. It publishes reviews, research articles, communications and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. Full experimental and/or methodical details must be provided. Electronic files or software regarding the full details of the calculation and experimental procedure - if unable to be published in a normal way - can be deposited as supplementary material. This journal covers all topics related to antibodies and antigens, topics of interest include (but are not limited to): antibody-producing cells (including B cells), antibody structure and function, antibody-antigen interactions, Fc receptors, antibody manufacturing antibody engineering, antibody therapy, immunoassays, antibody diagnosis, tissue antigens, exogenous antigens, endogenous antigens, autoantigens, monoclonal antibodies, natural antibodies, humoral immune responses, immunoregulatory molecules.